ATC Group: J01XA Glycopeptide antibacterials

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01XA in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01X Other antibacterials
4 J01XA Glycopeptide antibacterials

Group J01XA contents

Code Title
J01XA01 Vancomycin
J01XA02 Teicoplanin
J01XA03 Telavancin
J01XA04
J01XA05

Active ingredients in J01XA

Active Ingredient

Dalbavancin is a bactericidal lipoglycopeptide. Its mechanism of action in susceptible Gram-positive bacteria involves interruption of cell wall synthesis by binding to the terminal D-alanyl-D-alanine of the stem peptide in nascent cell wall peptidoglycan, preventing cross-linking (transpeptidation and transglycosylation) of disaccharide subunits resulting in bacterial cell death.

Oritavancin is used for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).

Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.

Vancomycin is a tricyclic glycopeptide antibiotic that inhibits the synthesis of the cell wall in sensitive bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units.

Related product monographs

Document Type Information Source  
 ORBACTIV Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 TARGOCID Powder for solution for injection, infusion or oral solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 TENKASI Powder for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 VIBATIV Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 XYDALBA Powder for concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)